NFKB1 and Alzheimer disease: Its anti‐inflammatory effects are mediated through suppression of microglial and astrocytic activation, reduced release of pro‐inflammatory cytokines such as IL‐1β and TNF‐α, and inhibition of NF‐κB signaling, all of which help mitigate the chronic neuroinflammation implicated in AD progression (Capiralla et al. 2012).